AnodyneWiki

Enable 3Dmol.js
Collapse all
Light theme

3,4-Methylenedioxyamphetamine

Read
MDA
3,4-Methylenedioxyamphetamine
Salts
[]
3,4-Methylenedioxyamphetamine hydrochloride
Generated by the Chemistry Development Kit (http://github.com/cdk)
Molecular structure via molpic based on CDK
Physical properties
[]
179.22 g/mol [1]
AppearanceAlmost colorless oil [1]
Boiling point157 °C [1]
DecompositionWhen heated to decomposition it emits toxic fumes of /Nitrogen oxides/. [1]
1.6 [1]
Structural Identifiers
[]
C10H13NO2 [1]
1-(1,3-benzodioxol-5-yl)propan-2-amine [1]
CC(CC1=CC2=C(C=C1)OCO2)N [1]
InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3 [1]
InChIKeyNGBBVGZWCFBOGO-UHFFFAOYSA-N [1]
Pharmacokinetics[]
Elimination half-life8.4 – 10.9 hours
Duration of action5 – 8 hours (range 1 – 10 hours)[4]
Dosing[]
Oral
[]
Light≤ 118.8 mg(1x - 25%)
Common118.8 - 150 mg(2x - 50%)
Strong150 - 152.5 mg
Heavy152.5 - 157 mg
Extreme157 mg +(1x - 25%)
Statistically derived dosages via DBI-IGS
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

3,4-Methylenedioxyamphetamine (also known as Tenamfetamine, Methylenedioxyamphetamine, Tenamfetaminum, Love, methylene dioxyamphetamine, 1,3-Benzodioxole-5-ethanamine, α-methyl-, α-Methyl-1,3-benzodioxole-5-ethanamine, Tenanfetamina, EA-1299 or α-Methyl-3,4-(methylenedioxy)phenethylamine) is a entactogen and stimulant substance of the 3,4-methylenedioxyphenethylamine and amphetamine class.

Chemistry

Salts []

3,4-Methylenedioxyamphetamine is typically found in the form of its hydrochloride salt.

 []

3,4-Methylenedioxyamphetamine is a racemic mixture of the .

(R)-3,4-MethylenedioxyamphetamineGenerated by the Chemistry Development Kit (http://github.com/cdk)
(S)-3,4-MethylenedioxyamphetamineGenerated by the Chemistry Development Kit (http://github.com/cdk)
Stereoisomer enumberation with rdkit

Pharmacology

Metabolism

Subjective effects []

Experience reports []

There are currently 25+ experience reports involving 3,4-methylenedioxyamphetamine on :

 []

  • Australia: 3,4-Methylenedioxyamphetamine is a S9 substance.
  • Brazil: 3,4-Methylenedioxyamphetamine is a F2 substance.[3]
  • Canada: 3,4-Methylenedioxyamphetamine is a Schedule I substance.
  • Germany: 3,4-Methylenedioxyamphetamine is a Anlage I substance.
  • United Kingdom: 3,4-Methylenedioxyamphetamine is a Class A substance.
  • United States: 3,4-Methylenedioxyamphetamine is a Schedule I under the "Controlled Substances Act (CSA)".
  • United Nations: 3,4-Methylenedioxyamphetamine is a Schedule I substance.
  • European Union: 3,4-Methylenedioxyamphetamine is a Fully prohibited substance.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 1614, Tenamfetamine. Accessed May 7, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/1614

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. 3,4-Methylenedioxyamphetamine. UNII: XJZ28FJ27W. Global Substance Registration System. Accessed May 7, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/XJZ28FJ27W

  3. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. July 24, 2023. Accessed May 7, 2026. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451

  4. Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME. Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants. Neuropsychopharmacology. January 1, 2026; 51(2):476–485.